CN101472585B - 抗菌组合物 - Google Patents

抗菌组合物 Download PDF

Info

Publication number
CN101472585B
CN101472585B CN200780023251XA CN200780023251A CN101472585B CN 101472585 B CN101472585 B CN 101472585B CN 200780023251X A CN200780023251X A CN 200780023251XA CN 200780023251 A CN200780023251 A CN 200780023251A CN 101472585 B CN101472585 B CN 101472585B
Authority
CN
China
Prior art keywords
optional
compound
ethyl
benzothiazole
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780023251XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101472585A (zh
Inventor
D·J·海登
L·G·洽普勒斯基
N·J·帕尔玛
D·R·米切尔
J·F·阿瑟奥
C·R·斯蒂尔
T·拉杜瓦赫蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Europe Ltd
Original Assignee
Biota Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Europe Ltd filed Critical Biota Europe Ltd
Publication of CN101472585A publication Critical patent/CN101472585A/zh
Application granted granted Critical
Publication of CN101472585B publication Critical patent/CN101472585B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200780023251XA 2006-06-22 2007-06-21 抗菌组合物 Expired - Fee Related CN101472585B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0612428.3A GB0612428D0 (en) 2006-06-22 2006-06-22 Antibacterial agents
GB0612428.3 2006-06-22
PCT/GB2007/002314 WO2007148093A1 (en) 2006-06-22 2007-06-21 Antibacterial compositions

Publications (2)

Publication Number Publication Date
CN101472585A CN101472585A (zh) 2009-07-01
CN101472585B true CN101472585B (zh) 2013-12-04

Family

ID=36803739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780023251XA Expired - Fee Related CN101472585B (zh) 2006-06-22 2007-06-21 抗菌组合物

Country Status (21)

Country Link
US (2) US7977340B2 (OSRAM)
EP (1) EP2034997B1 (OSRAM)
JP (1) JP5309021B2 (OSRAM)
KR (1) KR101443795B1 (OSRAM)
CN (1) CN101472585B (OSRAM)
AU (1) AU2007262791B2 (OSRAM)
BR (1) BRPI0713501A2 (OSRAM)
CA (1) CA2655403C (OSRAM)
DK (1) DK2034997T3 (OSRAM)
EA (1) EA019748B1 (OSRAM)
ES (1) ES2403005T3 (OSRAM)
GB (1) GB0612428D0 (OSRAM)
IL (1) IL195687A (OSRAM)
MX (1) MX2008015706A (OSRAM)
MY (1) MY148682A (OSRAM)
NZ (1) NZ574313A (OSRAM)
PL (1) PL2034997T3 (OSRAM)
PT (1) PT2034997E (OSRAM)
SG (1) SG172676A1 (OSRAM)
WO (1) WO2007148093A1 (OSRAM)
ZA (1) ZA200900240B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0724349D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
JP2010511682A (ja) 2006-12-04 2010-04-15 アストラゼネカ アクチボラグ 抗菌性の多環系尿素化合物
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2321309A1 (en) * 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
EP2277870A1 (de) * 2009-06-24 2011-01-26 Bayer CropScience AG Substituierte Benzoxa(thia)zole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2012146246A (ru) 2010-03-31 2014-05-10 Актелион Фармасьютиклз Лтд Антибактериальные производные изохинолин-3-илмочевины
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
AU2011260097B2 (en) 2010-06-01 2015-01-22 Summit (Oxford) Limited Compounds for the treatment of clostridium difficile associated disease
CA2824519C (en) 2011-01-14 2020-06-16 Vertex Pharmaceuticals Incorporated Process of making gyrase and topoisomerase inhibitors
JP6085829B2 (ja) 2011-01-14 2017-03-01 スペロ トリネム， インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼｉｖ阻害剤
TW201309676A (zh) 2011-01-14 2013-03-01 Vertex Pharma 旋轉酶抑制劑（ｒ）－１－乙基－３－［５－［２－（１－羥基－１－甲基－乙基）嘧啶－５－基］－７－（四氫呋喃－２－基］－１ｈ－苯并咪唑－２－基］脲之固體形式
EP2663562B1 (en) 2011-01-14 2018-11-07 Spero Trinem, Inc. Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
TWI554515B (zh) 2011-06-20 2016-10-21 維泰克斯製藥公司 旋轉酶（ｇｙｒａｓｅ）及拓樸異構酶抑制劑之磷酸酯
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
WO2014015105A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014087431A1 (en) * 2012-12-09 2014-06-12 Council Of Scientific & Industrial Research One pot process for the conversion of aroyl chlorides to acyl thioureas
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
JP2017504662A (ja) 2014-02-03 2017-02-09 スペロ ジャイレース インク ポリミキシンを含む抗菌剤の組合せ
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
EP3227301A1 (de) * 2014-12-02 2017-10-11 Bayer CropScience AG Bicyclische verbindungen als schädlingsbekämpfungsmittel
WO2016127102A2 (en) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
CA3015768A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
JP7098630B2 (ja) 2017-01-10 2022-07-11 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
KR20190133667A (ko) 2017-03-24 2019-12-03 다이쇼 세이야꾸 가부시끼가이샤 2(1h)-퀴놀리논 유도체
CA3058183A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
US20220289705A1 (en) 2019-07-17 2022-09-15 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
CN116033828B (zh) 2020-07-02 2025-05-16 拜耳公司 作为害虫防治剂的杂环衍生物
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
CN116444376B (zh) * 2023-04-19 2024-01-26 德兴市德邦化工有限公司 一种3,5-二氯硝基苯的生产工艺
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides
CN119350937B (zh) * 2024-10-30 2025-08-12 广东豪之盛新材料有限公司 一种双组份气雾喷漆及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
WO2001057008A1 (en) * 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
WO2005012292A1 (en) * 2003-01-31 2005-02-10 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810988A (en) * 1968-11-01 1974-05-14 Ciba Geigy Ag Control of phytopathogenic fungi with n-benzothiazae-2-yl n-{40 {11 propylure
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
KR100526487B1 (ko) 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
WO2005037845A1 (en) 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
WO2001057008A1 (en) * 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
WO2005012292A1 (en) * 2003-01-31 2005-02-10 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP5309021B2 (ja) 2013-10-09
EA019748B1 (ru) 2014-06-30
WO2007148093A1 (en) 2007-12-27
PT2034997E (pt) 2013-01-24
IL195687A (en) 2013-12-31
NZ574313A (en) 2011-10-28
AU2007262791B2 (en) 2012-11-08
US20110263590A1 (en) 2011-10-27
MX2008015706A (es) 2009-03-31
KR20090029817A (ko) 2009-03-23
US7977340B2 (en) 2011-07-12
IL195687A0 (en) 2009-09-01
ZA200900240B (en) 2009-12-30
US8389516B2 (en) 2013-03-05
CN101472585A (zh) 2009-07-01
EP2034997A1 (en) 2009-03-18
CA2655403A1 (en) 2007-12-27
JP2009541289A (ja) 2009-11-26
GB0612428D0 (en) 2006-08-02
DK2034997T3 (da) 2013-02-11
EP2034997B1 (en) 2012-10-17
SG172676A1 (en) 2011-07-28
PL2034997T3 (pl) 2013-04-30
KR101443795B1 (ko) 2014-10-21
ES2403005T3 (es) 2013-05-13
BRPI0713501A2 (pt) 2012-03-13
MY148682A (en) 2013-05-31
US20090197877A1 (en) 2009-08-06
EA200900047A1 (ru) 2009-06-30
AU2007262791A1 (en) 2007-12-27
CA2655403C (en) 2014-02-04

Similar Documents

Publication Publication Date Title
CN101472585B (zh) 抗菌组合物
CN101553233B (zh) 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂
US7666879B2 (en) Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors
US7326788B2 (en) Quinolinone derivatives as inhibitors of c-fms kinase
JP2020158523A (ja) 新規ヒストンデアセチラーゼインヒビター
CN108290860B (zh) 作为plasmepsin v抑制剂的亚氨基四氢嘧啶酮衍生物
CN114728912A (zh) Mta-协同prmt5抑制剂
JP2021508722A (ja) 芳香族ビニルまたは芳香族エチル系誘導体、その製造方法、中間体、薬物組成物および使用
CN102015700A (zh) 抗菌稠合噻唑
CN107849040A (zh) 三环衍生化合物、其制备方法、和含有其的药物组合物
CN104125947A (zh) 杂环脲化合物
WO2020192570A1 (zh) 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用
US20120004221A1 (en) Antibacterial Compositions
CN101404989B (zh) 抗菌剂
CN101005843A (zh) 吡咯并三嗪激酶抑制剂
TWI794844B (zh) 包含經由鏈接子連接之2或更多芳基或雜芳基的新穎羰基亞肼基二氰化物化合物及其用途
WO2013032797A2 (en) Oxetane 3,3-dicarboxamide compounds and methods of making and using same
AU2019297409B2 (en) PqsR inverse agonists
CN102558172B (zh) 5,8-二取代-1,6-二氮杂萘-7-羰酰胺类化合物及其二聚体化合物,其制备方法和用途
CN105101959B (zh) 作为刺猬信号传导通路的抑制剂的含有环状磺酰胺的衍生物
CN101415701A (zh) 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
KR20180134380A (ko) 옥세탄-3-일옥시 치환을 갖는 항균성 2방향족 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BIOTA EUROPE CO., LTD.

Free format text: FORMER OWNER: PROLYSIS LTD.

Effective date: 20100906

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: OXFORD, UK TO: LONDON, UK

TA01 Transfer of patent application right

Effective date of registration: 20100906

Address after: London, England

Applicant after: Biota Europe Limited

Address before: Oxfordshire

Applicant before: Prolysis Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131204

Termination date: 20150621

EXPY Termination of patent right or utility model